Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
Date:5/2/2013

f long-term obligations1,0881,084  Warrant liability1,9883,422  Long term liabilities4,0884,253  Stockholders' equity60,26566,207Total liabilities and stockholders' equity$
75,354$
82,016Conference Call Details OncoGenex will host a conference call at 4:30 p.m. Eastern Time today, Thursday, May 2, 2013, to provide a business update and discuss the first quarter 2013 results.

A live event will be available on the Investor Relations section of the OncoGenex Web site at www.OncoGenex.com. Alternatively, you may access the live conference call by dialing 877-606-1416 (U.S. & Canada) or 707-287-9313 (International). A replay of the webcast will be available approximately two hours after the call and will be archived for 90 days.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE:  TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Li
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
2. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
3. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
4. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
6. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
7. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
8. Avion Pharmaceuticals, LLC., announces further expansion of their Womens Health Sales Team
9. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
10. Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
11. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...  CARsgen, a leader in the development of Chimeric ... variety of cancers, today announced the completion of a ... China -based healthcare private equity fund.   ... development of new therapeutics for liver, lung, stomach and ... Shanghai Renji Hospital, the company plans to initiate clinical ...
(Date:11/26/2014)... Nov. 26, 2014 The medical magnetic ... rate of 4%, with world market revenues for ... MRI and other types of medical imaging have ... of numerous medical conditions in children and adults, ... Kalorama,s report, Medical Imaging Markets , analyzes ...
(Date:11/26/2014)... DALLAS , November 25, 2014 ... Surgical Instruments Market by Power Source (Electric, Battery, ... Console, Cables, Blade, Burr, Cart), by Application (Orthopedic, ... 2019" published by MarketsandMarkets, the global Powered Surgical Instruments ... to $1.6 Billion in 2014 and is expected ...
Breaking Medicine Technology:CARsgen Completes Series A Financing 2Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4
(Date:11/26/2014)... Bunion Bootie, the newest and best ... early celebration of the early holiday shopping season. Starting ... the promotional price of $29.95 each (normally $33.95 ea). ... any automatic discounts applied when buying more than one ... for complete details. It’s simple: purchasing more Bunion Booties ...
(Date:11/26/2014)... November 26, 2014 Louisiana Back ... and specialists in minimally invasive spine surgery, announces ... into the rapidly growing provider network of orthopedic ... addition coincides with the network’s continuing success providing ... for Louisiana residents who are suffering from orthopedic ...
(Date:11/26/2014)... 2014 Sonoran Vein and Endovascular ... the Distinguished Preceptorship Award from The American ... in the advancement of nurse practitioners. The Distinguished ... who had made a significant contribution toward increasing ... Association of Nurse Practitioners (AANP) is the largest ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Youngsters who enter puberty ... study suggests. Early puberty was linked with a ... self-image and high anxiety levels, according to the researchers. ... as conflict with family and peers, and having friends ... found. Although the study found an association between ...
(Date:11/26/2014)... -- Teens prescribed anti-anxiety or sleep medications are ... other teens, a new study warns. The ... assessments on teenagers before prescribing these drugs to ... don,t realize the abuse potential," said lead researcher ... Michigan School of Nursing. "These drugs produce highly ...
Breaking Medicine News(10 mins):Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2
... 19 Healthcare,Technologies Ltd. (NASDAQ: HCTL ), announced ... scheduled for September 30,2007, will be held on December ... Arnon & Co., 1 Azrieli Center, Round Tower, 47th ... be asked to approve the previously,announced Asset Purchase Agreement ...
... may lower sperm count" do not tell the whole ... from the Harvard,School of Public Health in Boston presented ... was based on recollected intake,of soyfoods and not on ... issues, thus I feel the results should be viewed ...
... 18 West Pharmaceutical,Services, Inc. (NYSE: WST ... that it has decided to discontinue marketing the,Exubera ... the,Company,s customer, Nektar Therapeutics, Inc. The Company,s Tech ... Exubera inhalation device for Nektar. "We were ...
... Blocks inflammatory activity of two immune system molecules, researchers ... new twist on an old theory of drug treatment ... trial, a California company reports. , The idea is ... believed to play a major role in asthma by ...
... Republican Whip,Roy Blunt (Mo.) issued the following statement today ... the State,Children,s Health Insurance Program (SCHIP) to children from ... "Today,s vote brings to a close what,s been a ... their energy to scoring,political points, and none of it ...
... 18 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI;,TSX: QLT) ... of,privately held ForSight Newco II, Inc. Through this ... to commercialize,ForSight Newco II,s proprietary ocular punctal plug ... development efforts in this program. "We are ...
Cached Medicine News:Health News:Healthcare Technologies Announces New Date for the Shareholders Meeting to Approve the Nexgen Biofuels Transaction 2Health News:Healthcare Technologies Announces New Date for the Shareholders Meeting to Approve the Nexgen Biofuels Transaction 3Health News:Real Men Eat Soy: The Truth about Soy and Sperm Count 2Health News:West Pharmaceutical Services Issues Statement on Exubera 2Health News:West Pharmaceutical Services Issues Statement on Exubera 3Health News:West Pharmaceutical Services Issues Statement on Exubera 4Health News:New Drug Eases Asthma Symptoms 2Health News:New Drug Eases Asthma Symptoms 3Health News:QLT Completes Acquisition of ForSight Newco II, Inc. 2Health News:QLT Completes Acquisition of ForSight Newco II, Inc. 3
The new CR6-45NM non-mydriatic retinal camera is an ideal diagnostic tool for ophthalmologists, optometrists and other medical professionals, especially when it comes to detecting and monitoring diab...
An ideal choice for film photography. The new TRC-50FXC provides 35mm color and Polaroid capability....
Digital imaging for optical screening: Diabetes, glaucoma macular degeneration, and other retinal disease....
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
Medicine Products: